JP2010526104A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010526104A5 JP2010526104A5 JP2010506700A JP2010506700A JP2010526104A5 JP 2010526104 A5 JP2010526104 A5 JP 2010526104A5 JP 2010506700 A JP2010506700 A JP 2010506700A JP 2010506700 A JP2010506700 A JP 2010506700A JP 2010526104 A5 JP2010526104 A5 JP 2010526104A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- amount
- plasma concentration
- sufficient
- blood sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 230000036470 plasma concentration Effects 0.000 claims 16
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 13
- 239000008280 blood Substances 0.000 claims 12
- 210000004369 blood Anatomy 0.000 claims 12
- BBPRUNPUJIUXSE-DXKRWKNPSA-N ifetroban Chemical group CCCCCNC(=O)C1=COC([C@H]2[C@H]([C@@H]3CC[C@H]2O3)CC=2C(=CC=CC=2)CCC(O)=O)=N1 BBPRUNPUJIUXSE-DXKRWKNPSA-N 0.000 claims 10
- 229950004274 ifetroban Drugs 0.000 claims 10
- 238000000034 method Methods 0.000 claims 8
- 239000003146 anticoagulant agent Substances 0.000 claims 7
- 229960004676 antithrombotic agent Drugs 0.000 claims 7
- 208000007536 Thrombosis Diseases 0.000 claims 6
- 239000000556 agonist Substances 0.000 claims 6
- 229940122202 Thromboxane receptor antagonist Drugs 0.000 claims 4
- 239000002396 thromboxane receptor blocking agent Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 206010053567 Coagulopathies Diseases 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 230000035602 clotting Effects 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 1
- 229930182837 (R)-adrenaline Natural products 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960005139 epinephrine Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91578407P | 2007-05-03 | 2007-05-03 | |
| US91578507P | 2007-05-03 | 2007-05-03 | |
| US94728907P | 2007-06-29 | 2007-06-29 | |
| US94731607P | 2007-06-29 | 2007-06-29 | |
| PCT/US2008/062567 WO2008137793A1 (en) | 2007-05-03 | 2008-05-02 | Unit dose formulations and methods of treating and preventing thrombosis with thromboxane receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010526104A JP2010526104A (ja) | 2010-07-29 |
| JP2010526104A5 true JP2010526104A5 (enExample) | 2011-06-23 |
Family
ID=39943967
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010506698A Pending JP2010527331A (ja) | 2007-05-03 | 2008-05-02 | Ｔｐモジュレーターの、アスピリン感受性集団および他の集団における心血管障害の治療のための使用 |
| JP2010506700A Pending JP2010526104A (ja) | 2007-05-03 | 2008-05-02 | トロンボキサン受容体アンタゴニストを用いて血栓症を治療及び予防する単位用量製剤及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010506698A Pending JP2010527331A (ja) | 2007-05-03 | 2008-05-02 | Ｔｐモジュレーターの、アスピリン感受性集団および他の集団における心血管障害の治療のための使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20090012115A1 (enExample) |
| EP (2) | EP2144999A4 (enExample) |
| JP (2) | JP2010527331A (enExample) |
| KR (2) | KR20100037029A (enExample) |
| CN (2) | CN101711279A (enExample) |
| AU (2) | AU2008247439A1 (enExample) |
| CA (2) | CA2688319A1 (enExample) |
| IL (2) | IL201885A0 (enExample) |
| MX (2) | MX2009011745A (enExample) |
| WO (2) | WO2008137793A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100168137A1 (en) * | 2006-12-20 | 2010-07-01 | Johan Raud | Combination for use in the treatment of inflammatory disorders |
| WO2008087371A1 (en) * | 2007-01-16 | 2008-07-24 | Cardoz Ab | New combination for use in the treatment of inflammatory disorders |
| KR20130026504A (ko) * | 2010-07-14 | 2013-03-13 | 큠버랜드 에멀징 테크놀로지스 아이앤씨 | 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법 |
| US10016417B2 (en) | 2011-11-07 | 2018-07-10 | Diakron Pharmaceuticals, Inc. | Extended release formulation of a direct thrombin inhibitor |
| JP6183459B2 (ja) * | 2012-08-06 | 2017-08-23 | Jnc株式会社 | 合成コラーゲンを用いる二重抗血小板薬／アスピリン応答および反応性試験 |
| US12161632B2 (en) | 2014-05-16 | 2024-12-10 | Cumberland Pharmaceuticals Inc. | Compositions and methods of treating cardiac fibrosis with ifetroban |
| JP6273072B2 (ja) * | 2014-05-16 | 2018-01-31 | カンバーランド ファーマシューティカルズ，インコーポレーテッド | イフェトロバンにより心臓線維症を治療する組成物及び方法 |
| ES2984026T3 (es) * | 2015-06-16 | 2024-10-28 | Atxa Therapeutics Ltd | Antagonistas del receptor de tromboxano |
| KR102448406B1 (ko) * | 2015-06-30 | 2022-09-27 | 큠버랜드 파마슈티컬즈 인코포레이티드 | Ａｅｒｄ/천식에서 트롬복산 수용체 길항제 |
| EP3454850B1 (en) | 2016-05-11 | 2023-06-21 | Cumberland Pharmaceuticals Inc. | Compositions and methods of treating muscular dystrophy with thromboxane-a2 receptor antagonists |
| AU2021246444A1 (en) * | 2020-03-31 | 2022-10-20 | Martin Ogletree | Methods and pharmaceutical compositions of thromboxane A2 receptor antagonist for the treatment of COVID-19 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3895115A (en) * | 1974-03-01 | 1975-07-15 | Serono Ist Farm | Method of inhibiting platelet aggregation |
| US5071866A (en) * | 1989-07-31 | 1991-12-10 | Bristol-Myers Squibb Company | Arylpyrazole derivatives as anti-platelet agents |
| US5506248A (en) * | 1993-08-02 | 1996-04-09 | Bristol-Myers Squibb Company | Pharmaceutical compositions having good dissolution properties |
| US5605917A (en) * | 1994-12-22 | 1997-02-25 | Bristol-Myers Squibb Company | Method of treating dysmenorrhea employing an interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analog |
| US6509348B1 (en) * | 1998-11-03 | 2003-01-21 | Bristol-Myers Squibb Company | Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination |
| JP2005533830A (ja) * | 2002-07-09 | 2005-11-10 | ビー．エム．アール．エイ． コーポレイション ベスローテン フェンノートシャップ | トロンボキサンａ２受容体アンタゴニストおよびｃｏｘ−２阻害剤の薬剤の組み合わせ |
| WO2006066008A2 (en) * | 2004-12-14 | 2006-06-22 | Portola Pharmaceuticals, Inc. | Device and methods for identifying and treating aspirin non-responsive patients |
| US7381536B2 (en) * | 2005-03-01 | 2008-06-03 | Gurbel Paul A | Assessment of cardiac health and thrombotic risk in a patient |
-
2008
- 2008-05-02 AU AU2008247439A patent/AU2008247439A1/en not_active Abandoned
- 2008-05-02 WO PCT/US2008/062567 patent/WO2008137793A1/en not_active Ceased
- 2008-05-02 KR KR1020097025330A patent/KR20100037029A/ko not_active Withdrawn
- 2008-05-02 MX MX2009011745A patent/MX2009011745A/es not_active Application Discontinuation
- 2008-05-02 KR KR1020097025329A patent/KR20100032854A/ko not_active Withdrawn
- 2008-05-02 EP EP08747593A patent/EP2144999A4/en active Pending
- 2008-05-02 CA CA002688319A patent/CA2688319A1/en not_active Abandoned
- 2008-05-02 MX MX2009011744A patent/MX2009011744A/es not_active Application Discontinuation
- 2008-05-02 JP JP2010506698A patent/JP2010527331A/ja active Pending
- 2008-05-02 AU AU2008247441A patent/AU2008247441A1/en not_active Abandoned
- 2008-05-02 CN CN200880014605A patent/CN101711279A/zh active Pending
- 2008-05-02 US US12/114,642 patent/US20090012115A1/en not_active Abandoned
- 2008-05-02 EP EP08747595A patent/EP2146573A4/en not_active Withdrawn
- 2008-05-02 JP JP2010506700A patent/JP2010526104A/ja active Pending
- 2008-05-02 CA CA002688317A patent/CA2688317A1/en not_active Abandoned
- 2008-05-02 CN CN200880019332A patent/CN101686668A/zh active Pending
- 2008-05-02 US US12/114,646 patent/US20090012136A1/en not_active Abandoned
- 2008-05-02 WO PCT/US2008/062565 patent/WO2008137791A1/en not_active Ceased
-
2009
- 2009-11-02 IL IL201885A patent/IL201885A0/en unknown
- 2009-11-02 IL IL201886A patent/IL201886A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Callebert et al. | Evidence for a control of plasma serotonin levels by 5-hydroxytryptamine2B receptors in mice | |
| Niitsu et al. | Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity | |
| Sugidachi et al. | Antiplatelet action of R‐99224, an active metabolite of a novel thienopyridine‐type Gi‐linked P2T antagonist, CS‐747 | |
| Gurbel et al. | Drug insight: clopidogrel nonresponsiveness | |
| Sugidachi et al. | The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metabolite | |
| de Abajo | Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients | |
| JP6250671B2 (ja) | 免疫関連及び炎症性疾患の治療 | |
| US20110269703A1 (en) | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy | |
| S. Tantry et al. | Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring | |
| Gurbel et al. | Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients | |
| TW201031651A (en) | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy | |
| JP2009504737A (ja) | 脈管疾患の治療又は予防のためのｐａｒ−１／ｐａｒ−４阻害剤の使用 | |
| CN101711279A (zh) | Tp调节剂在阿司匹林敏感群体以及其他群体中治疗心血管疾病的用途 | |
| Magnussen et al. | Paroxetine, a potent selective long-acting inhibitor of synaptosomal 5-HT uptake in mice | |
| Ferreiro et al. | Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation | |
| Serebruany et al. | Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial | |
| Leadbeater et al. | Aspirin has little additional anti‐platelet effect in healthy volunteers receiving prasugrel | |
| Spreux-Varoquaux et al. | Initial increase of plasma serotonin: a biological predictor for the antidepressant response to clomipramine? | |
| Yuhki et al. | Prostaglandin I2 plays a key role in zymosan-induced mouse pleurisy | |
| US20100056564A1 (en) | Association of an anti-atherothrombotic agent and an anti-platelet-aggregation agent | |
| EP1940402A4 (en) | AGONISTS OF THE NIACIN RECEPTOR, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT PROCEDURES | |
| WO2017031300A1 (en) | Composition and method for inhibiting platelet aggregation | |
| JP2010540461A (ja) | セロトニン二重作用化合物に関する併用療法 | |
| Kim et al. | Evaluation of anti-platelet and anti-thrombotic effects of cilostazol with PFA-100® and Multiplate® whole blood aggregometer in vitro, ex vivo and FeCl3-induced thrombosis models in vivo | |
| PT1505965E (pt) | Uso de valsartan ou do seu metabolito para inibir a agragação de plaquetas |